Fibrocell Science Inc (NASDAQ:FCSC) shares saw unusually-high trading volume on Thursday following insider buying activity. Approximately 1,577,965 shares changed hands during mid-day trading, an increase of 1,176% from the previous session’s volume of 123,641 shares.The stock last traded at $0.70 and had previously closed at $0.65.

Specifically, major shareholder Randal J. Kirk acquired 2,727,273 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The stock was purchased at an average cost of $0.77 per share, with a total value of $2,100,000.21. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.10% of the company’s stock.

A number of equities analysts have issued reports on FCSC shares. HC Wainwright reissued a “buy” rating and set a $5.70 price target on shares of Fibrocell Science in a research report on Friday, September 15th. Zacks Investment Research raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. ValuEngine lowered shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. Finally, Canaccord Genuity reissued a “buy” rating and set a $7.00 price target (up from $3.00) on shares of Fibrocell Science in a research report on Monday, September 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $5.21.

A hedge fund recently bought a new stake in Fibrocell Science stock. Pura Vida Investments LLC bought a new stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 297,000 shares of the company’s stock, valued at approximately $909,000. Pura Vida Investments LLC owned approximately 2.02% of Fibrocell Science at the end of the most recent reporting period. 55.81% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Fibrocell Science (FCSC) Sees Unusually-High Trading Volume Following Insider Buying Activity” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/14/fibrocell-science-fcsc-sees-unusually-high-trading-volume-following-insider-buying-activity.html.

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Stock Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related stocks with our FREE daily email newsletter.